CA-based Imbed Biosciences Secures $10M in Convertible Debt Funding. Together with current investors, Niterra took part in the round via the CVC fund that is jointly managed by Pegasus Tech Ventures and Niterra.
The funding will go towards expanding sales channels, advancing innovation, and scaling up commercial operations.
Read also – Tenn-based Reimagine Care Secures an Investment
Imbed is a commercial growth stage biotech firm registered with the FDA as a medical device manufacturer with an ISO 13485 certified quality management system. It is led by Ankit Agarwal, PhD, co-founder and chief scientific and quality officer.
Imbed has created a completely synthetic, antimicrobial wound matrix composed of biocompatible polymers. The FDA has approved this product for use in treating burns, skin grafts, chronic wounds, and surgical wounds, among other conditions.
Read also – Cambridge-based Ceretype Neuromedicine Secures its Second Round of Seed Funding
The antimicrobial matrix inhibits the formation of bacteria and biofilms while fostering a healing environment that promotes tissue growth.
About Imbed Biosciences
A privately held business, Imbed Biosciences Inc. is being recognised as a pioneer in the creation of cutting-edge medical equipment for the healing of burns, wounds, and soft tissue damage. Imbed Biosciences maintains a Quality Management System accredited to ISO 13485:2016 and is registered as a medical device manufacturer with the U.S. FDA.
Read also – Moonwalk Biosciences Raises $57 Mn Seed and Series A Funding
